Literature DB >> 2570437

Treatment of panic disorder: nonbenzodiazepine anxiolytics, including buspirone.

D S Robinson, R C Shrotriya, D R Alms, M Messina, J Andary.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2570437

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN： 0048-5764


× No keyword cloud information.
  5 in total

Review 1.  5-HT1A partial agonists. What is their future?

Authors:  D A Glitz; R Pohl
Journal:  Drugs       Date:  1991-01       Impact factor: 9.546

2.  Effects of the 5-HT1A receptor agonist flesinoxan in panic disorder.

Authors:  I M van Vliet; H G Westenberg; J A den Boer
Journal:  Psychopharmacology (Berl)       Date:  1996-09       Impact factor: 4.530

Review 3.  A risk-benefit assessment of buspirone in the treatment of anxiety disorders.

Authors:  J C Pecknold
Journal:  Drug Saf       Date:  1997-02       Impact factor: 5.606

4.  Conditioned ultrasonic distress vocalizations in adult male rats as a behavioural paradigm for screening anti-panic drugs.

Authors:  H E Molewijk; A M van der Poel; J Mos; J A van der Heyden; B Olivier
Journal:  Psychopharmacology (Berl)       Date:  1995-01       Impact factor: 4.530

Review 5.  Panic disorder. Pathophysiology and drug treatment.

Authors:  M R Johnson; R B Lydiard; J C Ballenger
Journal:  Drugs       Date:  1995-03       Impact factor: 9.546
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.